메뉴 건너뛰기




Volumn 58, Issue 6, 2010, Pages 819-828

Integrating surgery with targeted therapies for renal cell carcinoma: Current evidence and ongoing trials

Author keywords

Neoadjuvant therapy; Renal cell carcinoma; Tyrosine kinase inhibitor; Vascular endothelial growth factor

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AXITINIB; CEDIRANIB; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EVEROLIMUS; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TIVOZANIB; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

EID: 78049484272     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.08.029     Document Type: Review
Times cited : (92)

References (78)
  • 1
    • 42649145828 scopus 로고    scopus 로고
    • Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review
    • K. Gupta, J.D. Miller, J.Z. Li, M.W. Russell, and C. Charbonneau Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review Cancer Treat Rev 34 2008 193 205
    • (2008) Cancer Treat Rev , vol.34 , pp. 193-205
    • Gupta, K.1    Miller, J.D.2    Li, J.Z.3    Russell, M.W.4    Charbonneau, C.5
  • 4
    • 77249178172 scopus 로고    scopus 로고
    • A survey of therapy for advanced renal cell carcinoma
    • M. Basso, A. Cassano, and C. Barone A survey of therapy for advanced renal cell carcinoma Urol Oncol 28 2009 121 133
    • (2009) Urol Oncol , vol.28 , pp. 121-133
    • Basso, M.1    Cassano, A.2    Barone, C.3
  • 5
    • 1442290393 scopus 로고    scopus 로고
    • Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma
    • R.J. Motzer, J. Bacik, and L.H. Schwartz Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma J Clin Oncol 22 2004 454 463
    • (2004) J Clin Oncol , vol.22 , pp. 454-463
    • Motzer, R.J.1    Bacik, J.2    Schwartz, L.H.3
  • 6
    • 27144517504 scopus 로고    scopus 로고
    • Kidney cancer. v.2 National Comprehensive Cancer Network Web site AccessedFebruary2010
    • NCCN clinical practice guidelines in oncology. Kidney cancer. v.2, 2010. National Comprehensive Cancer Network Web site. http://www.nccn.org/ professionals/physician-gls/PDF/kidney.pdf. Accessed February 2010.
    • (2010) NCCN Clinical Practice Guidelines in Oncology
  • 8
    • 33846181370 scopus 로고    scopus 로고
    • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    • R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
    • (2007) N Engl J Med , vol.356 , pp. 115-124
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 9
    • 33846148701 scopus 로고    scopus 로고
    • Sorafenib in advanced clear-cell renal-cell carcinoma
    • B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
    • (2007) N Engl J Med , vol.356 , pp. 125-134
    • Escudier, B.1    Eisen, T.2    Stadler, W.M.3
  • 10
    • 77949890945 scopus 로고    scopus 로고
    • Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial
    • C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
    • (2010) J Clin Oncol , vol.28 , pp. 1061-1068
    • Sternberg, C.N.1    Davis, I.D.2    Mardiak, J.3
  • 11
    • 37349080670 scopus 로고    scopus 로고
    • Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial
    • B. Escudier, A. Pluzanska, and P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111
    • (2007) Lancet , vol.370 , pp. 2103-2111
    • Escudier, B.1    Pluzanska, A.2    Koralewski, P.3
  • 12
    • 56749161699 scopus 로고    scopus 로고
    • Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
    • B.I. Rini, S. Halabi, and J.E. Rosenberg Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 2008 5422 5428
    • (2008) J Clin Oncol , vol.26 , pp. 5422-5428
    • Rini, B.I.1    Halabi, S.2    Rosenberg, J.E.3
  • 13
    • 48649107474 scopus 로고    scopus 로고
    • Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial
    • R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
    • (2008) Lancet , vol.372 , pp. 449-456
    • Motzer, R.J.1    Escudier, B.2    Oudard, S.3
  • 15
    • 0035818877 scopus 로고    scopus 로고
    • Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
    • R.C. Flanigan, S.E. Salmon, and B.A. Blumenstein Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 2001 1655 1659
    • (2001) N Engl J Med , vol.345 , pp. 1655-1659
    • Flanigan, R.C.1    Salmon, S.E.2    Blumenstein, B.A.3
  • 16
    • 0035934596 scopus 로고    scopus 로고
    • Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial
    • G.H. Mickisch, A. Garin, H. van Poppel, L. de Prijck, and R. Sylvester Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 2001 966 970
    • (2001) Lancet , vol.358 , pp. 966-970
    • Mickisch, G.H.1    Garin, A.2    Van Poppel, H.3    De Prijck, L.4    Sylvester, R.5
  • 17
    • 1542327748 scopus 로고    scopus 로고
    • Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis
    • R.C. Flanigan, G. Mickisch, R. Sylvester, C. Tangen, H. Van Poppel, and E*D. Crawford Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis J Urol 171 2004 1071 1076
    • (2004) J Urol , vol.171 , pp. 1071-1076
    • Flanigan, R.C.1    Mickisch, G.2    Sylvester, R.3    Tangen, C.4    Van Poppel, H.5    Crawford, E.D.6
  • 18
    • 77949451507 scopus 로고    scopus 로고
    • Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy
    • E.J. Abel, and C.G. Wood Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy Nat Rev Urol 6 2009 375 383
    • (2009) Nat Rev Urol , vol.6 , pp. 375-383
    • Abel, E.J.1    Wood, C.G.2
  • 19
    • 0034845956 scopus 로고    scopus 로고
    • Histopathologic analysis of angiogenic factors in localized renal cell carcinoma: The influence of neoadjuvant treatment
    • N. Kawata, H. Yagasaki, and H. Yuge Histopathologic analysis of angiogenic factors in localized renal cell carcinoma: the influence of neoadjuvant treatment Int J Urol 8 2001 275 281
    • (2001) Int J Urol , vol.8 , pp. 275-281
    • Kawata, N.1    Yagasaki, H.2    Yuge, H.3
  • 20
    • 0035131552 scopus 로고    scopus 로고
    • Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma
    • J.W. Slaton, K. Inoue, and P. Perrotte Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma Am J Pathol 158 2001 735 743
    • (2001) Am J Pathol , vol.158 , pp. 735-743
    • Slaton, J.W.1    Inoue, K.2    Perrotte, P.3
  • 21
    • 78049466218 scopus 로고    scopus 로고
    • Clinical trial to assess the importance of nephrectomy (CARMENA). US National Institutes of Health Web site AccessedJuly28,2010
    • Clinical trial to assess the importance of nephrectomy (CARMENA). US National Institutes of Health Web site. http://clinicaltrials.gov/ct2/show/ NCT00930033. Accessed July 28, 2010.
  • 22
    • 34548310217 scopus 로고    scopus 로고
    • Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors
    • R.J. Motzer, R.A. Figlin, and T.E. Hutson Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors J Clin Oncol 25 2007 5024
    • (2007) J Clin Oncol , vol.25 , pp. 5024
    • Motzer, R.J.1    Figlin, R.A.2    Hutson, T.E.3
  • 23
    • 78049486075 scopus 로고    scopus 로고
    • The impact of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy
    • March 5-7 San Francisco, CA, USA
    • Choueiri TK, Xie W, Kollmannsberger CK, et al. The impact of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy. Paper presented at: 2010 Genitourinary Cancers Symposium; March 5-7, 2010; San Francisco, CA, USA.
    • (2010) Paper Presented At: 2010 Genitourinary Cancers Symposium
    • Choueiri, T.K.1    Xie, W.2    Kollmannsberger, C.K.3
  • 24
    • 70450159233 scopus 로고    scopus 로고
    • A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment
    • M. Warren, P.M. Venner, and S. North A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment Can Urol Assoc J 3 2009 281 289
    • (2009) Can Urol Assoc J , vol.3 , pp. 281-289
    • Warren, M.1    Venner, P.M.2    North, S.3
  • 25
    • 58149183664 scopus 로고    scopus 로고
    • Predictors of survival of advanced renal cell carcinoma: Long-term results from Southwest Oncology Group Trial S8949
    • P.N. Lara Jr., C.M. Tangen, S.J. Conlon, R.C. Flanigan, and E.D. Crawford Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949 J Urol 181 2009 512 516 discussion 516-7
    • (2009) J Urol , vol.181 , pp. 512-516
    • Lara, Jr.P.N.1    Tangen, C.M.2    Conlon, S.J.3    Flanigan, R.C.4    Crawford, E.D.5
  • 26
    • 68949145218 scopus 로고    scopus 로고
    • Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
    • R.J. Motzer, T.E. Hutson, and P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
    • (2009) J Clin Oncol , vol.27 , pp. 3584-3590
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 27
    • 58149181329 scopus 로고    scopus 로고
    • Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma
    • A.A. Thomas, B.I. Rini, and B.R. Lane Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma J Urol 181 2009 518 523 discussion 523
    • (2009) J Urol , vol.181 , pp. 518-523
    • Thomas, A.A.1    Rini, B.I.2    Lane, B.R.3
  • 28
    • 65049087191 scopus 로고    scopus 로고
    • Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis
    • M. Johannsen, A. Flörcken, and A. Bex Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis Eur Urol 55 2009 1430 1439
    • (2009) Eur Urol , vol.55 , pp. 1430-1439
    • Johannsen, M.1    Flörcken, A.2    Bex, A.3
  • 29
    • 33846698219 scopus 로고    scopus 로고
    • Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases
    • B.I. Rini, V. Shaw, J.E. Rosenberg, S.T. Kim, and I. Chen Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases Clin Genitourin Cancer 5 2006 232 234
    • (2006) Clin Genitourin Cancer , vol.5 , pp. 232-234
    • Rini, B.I.1    Shaw, V.2    Rosenberg, J.E.3    Kim, S.T.4    Chen, I.5
  • 31
    • 52949083899 scopus 로고    scopus 로고
    • Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy
    • C. Amin, E. Wallen, R.S. Pruthi, B.F. Calvo, P.A. Godley, and W.K. Rathmell Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy Urology 72 2008 864 868
    • (2008) Urology , vol.72 , pp. 864-868
    • Amin, C.1    Wallen, E.2    Pruthi, R.S.3    Calvo, B.F.4    Godley, P.A.5    Rathmell, W.K.6
  • 32
    • 46249087574 scopus 로고    scopus 로고
    • Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy
    • F. Di Silverio, A. Sciarra, and U. Parente Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy Urol Int 80 2008 451 453
    • (2008) Urol Int , vol.80 , pp. 451-453
    • Di Silverio, F.1    Sciarra, A.2    Parente, U.3
  • 33
    • 50049092572 scopus 로고    scopus 로고
    • Neoadjuvant targeted therapy and advanced kidney cancer: Observations and implications for a new treatment paradigm
    • B. Shuch, S.B. Riggs, and J.C. LaRochelle Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm BJU Int 102 2008 692 696
    • (2008) BJU Int , vol.102 , pp. 692-696
    • Shuch, B.1    Riggs, S.B.2    Larochelle, J.C.3
  • 34
    • 43849100292 scopus 로고    scopus 로고
    • Neoadjuvant therapy for renal cancer [in French]
    • F. Thibault, O. Rixe, and J.B. Meric Neoadjuvant therapy for renal cancer [in French] Prog Urol 18 2008 256 258
    • (2008) Prog Urol , vol.18 , pp. 256-258
    • Thibault, F.1    Rixe, O.2    Meric, J.B.3
  • 35
    • 44649192971 scopus 로고    scopus 로고
    • Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma
    • V. Margulis, S.F. Matin, and N. Tannir Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma J Urol 180 2008 94 98
    • (2008) J Urol , vol.180 , pp. 94-98
    • Margulis, V.1    Matin, S.F.2    Tannir, N.3
  • 36
    • 35548987275 scopus 로고    scopus 로고
    • Perioperative sunitinib dosing around extensive resections of imatinib-resistant metastatic gastrointestinal stromal tumors
    • C. Raut, J. Morgan, and M. Quigley Perioperative sunitinib dosing around extensive resections of imatinib-resistant metastatic gastrointestinal stromal tumors J Clin Oncol 25 2007 10044
    • (2007) J Clin Oncol , vol.25 , pp. 10044
    • Raut, C.1    Morgan, J.2    Quigley, M.3
  • 37
    • 42249091688 scopus 로고    scopus 로고
    • Sunitinib for treatment of advanced renal cell cancer: Primary tumor response
    • A.A. Van der Veldt, M.R. Meijerink, and A.J. van den Eertwegh Sunitinib for treatment of advanced renal cell cancer: primary tumor response Clin Cancer Res 14 2008 2431 2436
    • (2008) Clin Cancer Res , vol.14 , pp. 2431-2436
    • Van Der Veldt, A.A.1    Meijerink, M.R.2    Van Den Eertwegh, A.J.3
  • 38
    • 39749085432 scopus 로고    scopus 로고
    • Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers
    • M. Guix, M. Granja Nde, and I. Meszoely Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers J Clin Oncol 26 2008 897 906
    • (2008) J Clin Oncol , vol.26 , pp. 897-906
    • Guix, M.1    Granja Nde, M.2    Meszoely, I.3
  • 39
    • 33846867459 scopus 로고    scopus 로고
    • Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: Combining surgery and systemic therapies to improve patient outcome
    • C.G. Wood Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome Clin Cancer Res 13 2007 697s 702s
    • (2007) Clin Cancer Res , vol.13
    • Wood, C.G.1
  • 40
    • 70249115638 scopus 로고    scopus 로고
    • Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma
    • E. Jonasch, C.G. Wood, and S.F. Matin Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 4076 4081
    • (2009) J Clin Oncol , vol.27 , pp. 4076-4081
    • Jonasch, E.1    Wood, C.G.2    Matin, S.F.3
  • 41
    • 78049455213 scopus 로고    scopus 로고
    • Immediate surgery or surgery after sunitinib malate in treating patients with metastatic kidney cancer. US National Institutes of Health Web site AccessedMay5,2010
    • Immediate surgery or surgery after sunitinib malate in treating patients with metastatic kidney cancer. US National Institutes of Health Web site. http://clinicaltrials.gov/ct2/show/NCT01099423. Accessed May 5, 2010.
  • 42
    • 33749451335 scopus 로고    scopus 로고
    • Adjuvant therapy for renal cell carcinoma
    • K.M. Jacobsohn, and C.G. Wood Adjuvant therapy for renal cell carcinoma Semin Oncol 33 2006 576 582
    • (2006) Semin Oncol , vol.33 , pp. 576-582
    • Jacobsohn, K.M.1    Wood, C.G.2
  • 43
    • 10744230275 scopus 로고    scopus 로고
    • Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial
    • D. Jocham, A. Richter, and L. Hoffmann Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial Lancet 363 2004 594 599
    • (2004) Lancet , vol.363 , pp. 594-599
    • Jocham, D.1    Richter, A.2    Hoffmann, L.3
  • 44
    • 46749085802 scopus 로고    scopus 로고
    • An adjuvant autologous therapeutic vaccine (HSPPC-96; Vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: A multicentre, open-label, randomised phase III trial
    • C. Wood, P. Srivastava, and R. Bukowski An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial Lancet 372 2008 145 154
    • (2008) Lancet , vol.372 , pp. 145-154
    • Wood, C.1    Srivastava, P.2    Bukowski, R.3
  • 45
    • 58149115366 scopus 로고    scopus 로고
    • Adjuvant therapy for renal cell carcinoma
    • N.B. Haas, and R. Uzzo Adjuvant therapy for renal cell carcinoma Curr Oncol Rep 10 2008 245 252
    • (2008) Curr Oncol Rep , vol.10 , pp. 245-252
    • Haas, N.B.1    Uzzo, R.2
  • 46
    • 65649108112 scopus 로고    scopus 로고
    • Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: Impact of therapy on recurrence patterns and outcome measures
    • E.R. Plimack, N. Tannir, E. Lin, B.N. Bekele, and E. Jonasch Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures Cancer 115 2009 1859 1866
    • (2009) Cancer , vol.115 , pp. 1859-1866
    • Plimack, E.R.1    Tannir, N.2    Lin, E.3    Bekele, B.N.4    Jonasch, E.5
  • 47
    • 60649087564 scopus 로고    scopus 로고
    • Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
    • J.M. Ebos, C.R. Lee, W. Cruz-Munoz, G.A. Bjarnason, J.G. Christensen, and R.S. Kerbel Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 2009 232 239
    • (2009) Cancer Cell , vol.15 , pp. 232-239
    • Ebos, J.M.1    Lee, C.R.2    Cruz-Munoz, W.3    Bjarnason, G.A.4    Christensen, J.G.5    Kerbel, R.S.6
  • 48
    • 60649106195 scopus 로고    scopus 로고
    • Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
    • M. Paez-Ribes, E. Allen, and J. Hudock Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 2009 220 231
    • (2009) Cancer Cell , vol.15 , pp. 220-231
    • Paez-Ribes, M.1    Allen, E.2    Hudock, J.3
  • 49
    • 69349105667 scopus 로고    scopus 로고
    • Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma
    • A. Kapoor, A. Gharajeh, A. Sheikh, and J. Pinthus Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma Curr Oncol 16 2009 S60 S66
    • (2009) Curr Oncol , vol.16
    • Kapoor, A.1    Gharajeh, A.2    Sheikh, A.3    Pinthus, J.4
  • 50
    • 34248369806 scopus 로고    scopus 로고
    • The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy
    • B.I. Rini, and S.C. Campbell The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy J Urol 177 2007 1978 1984
    • (2007) J Urol , vol.177 , pp. 1978-1984
    • Rini, B.I.1    Campbell, S.C.2
  • 51
    • 70749100131 scopus 로고    scopus 로고
    • Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib
    • L.C. Harshman, S. Srinivas, A. Kamaya, and B.I. Chung Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib Nat Rev Urol 6 2009 338 343
    • (2009) Nat Rev Urol , vol.6 , pp. 338-343
    • Harshman, L.C.1    Srinivas, S.2    Kamaya, A.3    Chung, B.I.4
  • 52
    • 39449121694 scopus 로고    scopus 로고
    • Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi
    • P.I. Karakiewicz, N. Suardi, and C. Jeldres Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi Eur Urol 53 2008 845 848
    • (2008) Eur Urol , vol.53 , pp. 845-848
    • Karakiewicz, P.I.1    Suardi, N.2    Jeldres, C.3
  • 53
    • 56249123229 scopus 로고    scopus 로고
    • Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma
    • J.-J. Patard, R. Thuret, A. Raffi, B. Laguerre, K. Bensalah, and S. Culine Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma Eur Urol 55 2009 237 239 quiz 239
    • (2009) Eur Urol , vol.55 , pp. 237-239
    • Patard, J.-J.1    Thuret, R.2    Raffi, A.3    Laguerre, B.4    Bensalah, K.5    Culine, S.6
  • 54
    • 66249097161 scopus 로고    scopus 로고
    • Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma
    • G. Robert, G. Gabbay, and R. Bram Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma Eur Urol 55 2009 1477 1480
    • (2009) Eur Urol , vol.55 , pp. 1477-1480
    • Robert, G.1    Gabbay, G.2    Bram, R.3
  • 55
    • 68549091054 scopus 로고    scopus 로고
    • Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: Initial experience with downsizing to reconsider cytoreductive surgery
    • A. Bex, A.A. van der Veldt, and C. Blank Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery World J Urol 27 2009 533 539
    • (2009) World J Urol , vol.27 , pp. 533-539
    • Bex, A.1    Van Der Veldt, A.A.2    Blank, C.3
  • 58
    • 76249126867 scopus 로고    scopus 로고
    • Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma
    • Huang D, Ding Y, Li Y, et al. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 70:1053-62.
    • Cancer Res , vol.70 , pp. 1053-62
    • Huang, D.1    Ding, Y.2    Li, Y.3
  • 59
    • 78049458544 scopus 로고    scopus 로고
    • Sunitinib in treating patients with kidney cancer that cannot be removed by surgery. US National Institutes of Health Web site AccessedMay5,2010
    • Sunitinib in treating patients with kidney cancer that cannot be removed by surgery. US National Institutes of Health Web site. http://clinicaltrials. gov/ct2/show/NCT00459979?term=kidney+cancer+surgery&rank=13. Accessed May 5, 2010.
  • 60
    • 68149125532 scopus 로고    scopus 로고
    • Surgical resection of renal cell carcinoma after targeted therapy
    • A.A. Thomas, B.I. Rini, and A.J. Stephenson Surgical resection of renal cell carcinoma after targeted therapy J Urol 182 2009 881 886
    • (2009) J Urol , vol.182 , pp. 881-886
    • Thomas, A.A.1    Rini, B.I.2    Stephenson, A.J.3
  • 61
    • 33748807076 scopus 로고    scopus 로고
    • Molecular mechanisms of VEGF-A action during tissue repair
    • S.A. Eming, and T. Krieg Molecular mechanisms of VEGF-A action during tissue repair J Investig Dermatol Symp Proc 11 2006 79 86
    • (2006) J Investig Dermatol Symp Proc , vol.11 , pp. 79-86
    • Eming, S.A.1    Krieg, T.2
  • 62
    • 33845490014 scopus 로고    scopus 로고
    • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    • A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
    • (2006) N Engl J Med , vol.355 , pp. 2542-2550
    • Sandler, A.1    Gray, R.2    Perry, M.C.3
  • 63
    • 34548141828 scopus 로고    scopus 로고
    • Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab
    • F.A. Scappaticci, J.R. Skillings, and S.N. Holden Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab J Natl Cancer Inst 99 2007 1232 1239
    • (2007) J Natl Cancer Inst , vol.99 , pp. 1232-1239
    • Scappaticci, F.A.1    Skillings, J.R.2    Holden, S.N.3
  • 64
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
    • (2004) N Engl J Med , vol.350 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3
  • 65
    • 21244481589 scopus 로고    scopus 로고
    • High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200
    • B.J. Giantonio, P.J. Catalano, and N.J. Meropol High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 J Clin Oncol 23 2005 2
    • (2005) J Clin Oncol , vol.23 , pp. 2
    • Giantonio, B.J.1    Catalano, P.J.2    Meropol, N.J.3
  • 66
    • 77951886671 scopus 로고    scopus 로고
    • Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma
    • C.L. Cowey, C. Amin, and R.S. Pruthi Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma J Clin Oncol 28 2010 1502 1507
    • (2010) J Clin Oncol , vol.28 , pp. 1502-1507
    • Cowey, C.L.1    Amin, C.2    Pruthi, R.S.3
  • 67
    • 3242713145 scopus 로고    scopus 로고
    • Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey
    • D. Dindo, N. Demartines, and P.A. Clavien Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey Ann Surg 240 2004 205 213
    • (2004) Ann Surg , vol.240 , pp. 205-213
    • Dindo, D.1    Demartines, N.2    Clavien, P.A.3
  • 68
    • 64549104195 scopus 로고    scopus 로고
    • Tolerability of first-line therapy for metastatic renal cell carcinoma
    • C. Porta, and C. Szczylik Tolerability of first-line therapy for metastatic renal cell carcinoma Cancer Treat Rev 35 2009 297 307
    • (2009) Cancer Treat Rev , vol.35 , pp. 297-307
    • Porta, C.1    Szczylik, C.2
  • 69
    • 39049095199 scopus 로고    scopus 로고
    • Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma
    • G. Sonpavde, T.E. Hutson, and C.N. Sternberg Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma Expert Opin Investig Drugs 17 2008 253 261
    • (2008) Expert Opin Investig Drugs , vol.17 , pp. 253-261
    • Sonpavde, G.1    Hutson, T.E.2    Sternberg, C.N.3
  • 70
    • 70449523183 scopus 로고    scopus 로고
    • Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
    • R. Kumar, M.C. Crouthamel, and D.H. Rominger Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors Br J Cancer 101 2009 1717 1723
    • (2009) Br J Cancer , vol.101 , pp. 1717-1723
    • Kumar, R.1    Crouthamel, M.C.2    Rominger, D.H.3
  • 71
    • 35448934762 scopus 로고    scopus 로고
    • Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: A phase II study
    • O. Rixe, R.M. Bukowski, and M.D. Michaelson Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Lancet Oncol 8 2007 975 984
    • (2007) Lancet Oncol , vol.8 , pp. 975-984
    • Rixe, O.1    Bukowski, R.M.2    Michaelson, M.D.3
  • 72
    • 36549025941 scopus 로고    scopus 로고
    • Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium
    • S.S. Sridhar, S.J. Hotte, and M.J. Mackenzie Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium J Clin Oncol 25 2007 5093
    • (2007) J Clin Oncol , vol.25 , pp. 5093
    • Sridhar, S.S.1    Hotte, S.J.2    MacKenzie, M.J.3
  • 73
    • 63449138139 scopus 로고    scopus 로고
    • Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium
    • S.S. Sridhar, M.J. Mackenzie, and S.J. Hotte Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium J Clin Oncol 26 2008 5047
    • (2008) J Clin Oncol , vol.26 , pp. 5047
    • Sridhar, S.S.1    MacKenzie, M.J.2    Hotte, S.J.3
  • 74
    • 78049475481 scopus 로고    scopus 로고
    • Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT)
    • P. Bhargava, B. Esteves, and M. Al-Adhami Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT) J Clin Oncol 28 2010 4599
    • (2010) J Clin Oncol , vol.28 , pp. 4599
    • Bhargava, P.1    Esteves, B.2    Al-Adhami, M.3
  • 75
    • 78049483284 scopus 로고    scopus 로고
    • Sunitinib or sorafenib in treating patients with kidney cancer that was removed by surgery. US National Institutes of Health Web site AccessedMay5,2010
    • Sunitinib or sorafenib in treating patients with kidney cancer that was removed by surgery. US National Institutes of Health Web site. http://clinicaltrials.gov/ct2/show/NCT00326898. Accessed May 5, 2010.
  • 76
    • 78049487131 scopus 로고    scopus 로고
    • A clinical trial comparing efficacy and safety of sunitinib versus placebo for the treatment of patients at high risk of recurrent renal cell cancer (S-TRAC). US National Institutes of Health Web site
    • A clinical trial comparing efficacy and safety of sunitinib versus placebo for the treatment of patients at high risk of recurrent renal cell cancer (S-TRAC). US National Institutes of Health Web site. http:// clinicaltrials.gov/ct2/show/NCT00375674. Accessed July 28, 2010.
  • 77
    • 78049482928 scopus 로고    scopus 로고
    • Sorafenib in treating patients at risk of relapse after undergoing surgery to remove kidney cancer. US National Institutes of Health Web site AccessedJuly28,2010
    • Sorafenib in treating patients at risk of relapse after undergoing surgery to remove kidney cancer. US National Institutes of Health Web site. http://clinicaltrials.gov/ct2/show/NCT00492258. Accessed July 28, 2010.
  • 78
    • 78049484172 scopus 로고    scopus 로고
    • Everolimus in treating patients with kidney cancer who have undergone surgery. US National Institutes of Health Web site
    • Everolimus in treating patients with kidney cancer who have undergone surgery. US National Institutes of Health Web site. http://clinicaltrials.gov/ ct2/show/NCT01120249?term=EVEREST&rank=7. Accessed May 5, 2010.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.